FOCIS goes south: advances in translational and clinical immunology.

Abstract:

:FOCIS goes South: Advances in Translational and Clinical Immunology was the first Federation of Clinical Immunology Societies (FOCIS) ( www.focisnet.org ) meeting held in Latin America (May 15-17, 2017, Santiago de Chile, Chile). The meeting was organized as a 3-day workshop and was fostered by the Millennium Institute on Immunology and Immunotherapy, a recently nominated FOCIS Center of Excellence. The workshop brought together FOCIS associates, such as members of the FOCIS Board of Directors, Directors of different Centers of Excellence, regional speakers and 350 attendees. The Meeting covered aspects of immune regulation and modulation, as well as immunotherapy in areas of autoimmunity, transplantation, cancer and infectious diseases, among others. The activity also had a full-day immunology course and a day-long flow cytometry course.

journal_name

Immunotherapy

journal_title

Immunotherapy

authors

Kalergis AM,Anegon I,González PA

doi

10.2217/imt-2017-0079

subject

Has Abstract

pub_date

2017-09-01 00:00:00

pages

789-792

issue

10

eissn

1750-743X

issn

1750-7448

journal_volume

9

pub_type

  • Characterization of monocyte-derived dendritic cells used in immunotherapy for HIV-1-infected individuals.

    abstract:AIMS:A therapeutic vaccine based on monocyte-derived dendritic cells (MDDCs) has been shown to represent a promising strategy for the treatment of cancer and viral infections. Here, we characterized the MDDCs used as an immunogen in a clinical trial for an anti-HIV-1 therapeutic vaccine. PATIENTS & METHODS:Monocytes o...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt-2017-0165

    authors: da Silva LT,da Silva WC,de Almeida A,da Silva Reis D,Santillo BT,Rigato PO,da Silva Duarte AJ,Oshiro TM

    更新日期:2018-08-01 00:00:00

  • Genetic modification of natural killer cells for adoptive cellular immunotherapy.

    abstract::Immunotherapy of cancer is a rapidly developing field; one such development is the manipulation and use of natural killer (NK) cells. These cells with 'killer instincts' are an attractive cell to utilize, as they are directly reactive toward tumor and could potentially activate the endogenous adaptive immune system. T...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.09.36

    authors: Pegram HJ,Kershaw MH,Darcy PK

    更新日期:2009-07-01 00:00:00

  • PROSTVAC® targeted immunotherapy candidate for prostate cancer.

    abstract::Targeted immunotherapies represent a valid strategy for the treatment of metastatic castrate-resistant prostate cancer. A randomized, double-blind, Phase II clinical trial of PROSTVAC® demonstrated a statistically significant improvement in overall survival and a large, global, Phase III trial with overall survival as...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.13.176

    authors: Shore ND

    更新日期:2014-01-01 00:00:00

  • Joint injury and osteoarthritis: soluble mediators in the course and treatment of cartilage pathology.

    abstract::Osteoarthritis is a disabling disease of the aging generation, which results in loss of quality of life and increased healthcare costs. Cytokines appear to play an important role in the cartilaginous degeneration characterizing the pathological process. Increasing experience is being gained with cytokine-modulating th...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.09.14

    authors: Rutgers M,Saris DB,Yang KG,Dhert WJ,Creemers LB

    更新日期:2009-05-01 00:00:00

  • Immunotherapy for pulmonary TB: antimicrobial peptides and their inducers.

    abstract::TB is an infectious disease that still has an enormous impact on public health worldwide. With the continuous increasing epidemic of multidrug-resistant TB, new drugs and vaccines are urgently needed. In the last decade there has been a broad advance in the knowledge of innate immunity in TB. Together with the growing...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.13.111

    authors: Rivas-Santiago CE,Hernández-Pando R,Rivas-Santiago B

    更新日期:2013-10-01 00:00:00

  • Recovery of COVID-19 acute respiratory distress syndrome with tocilizumab: successful outcome in two critically ill patients.

    abstract::Background: Severe pneumonia and acute respiratory distress syndrome (ARDS) due to COVID-19 is a challenge for nowadays medical practice. Although there is no clarity in the principal mechanism of lung damage and ARDS development, it has been suggested that one of the main reasons of this pathology is the hyperactivat...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt-2020-0154

    authors: Cala-García JD,Sierra-Bretón JD,Cavelier-Baiz JE,Faccini-Martínez ÁA,Pérez-Díaz CE

    更新日期:2020-10-01 00:00:00

  • Pembrolizumab in a BRAF-mutant metastatic melanoma patient following a severe immune-related adverse event with ipilimumab.

    abstract::Currently, limited data exist on the safety of pembrolizumab in patients with metastatic melanoma who have developed severe immune-related adverse events following treatment with ipilimumab. We report a 45-year-old male patient with BRAF-mutant metastatic melanoma who discontinued treatment with ipilimumab due to trea...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt-2015-0025

    authors: Aya F,Fernández-Martínez A,Gaba L,Victoria I,Tosca M,Carrera C,Prat A,Arance A

    更新日期:2016-06-01 00:00:00

  • Immortal time bias in the association between toxicity and response for immune checkpoint inhibitors: a meta-analysis.

    abstract::Only a minority of studies addressing the association between immune-related adverse events (IrAE) and outcome considered the immortal time bias, with conflicting results. PubMed, Embase, Web of Science and Scopus were searched through 2 January 2020. Studies reporting the impact of IrAE on outcome in patients treated...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt-2020-0179

    authors: Dall'Olio FG,Rizzo A,Mollica V,Massucci M,Maggio I,Massari F

    更新日期:2021-02-01 00:00:00

  • Anti-TNF therapeutics for the treatment of sarcoidosis.

    abstract::Sarcoidosis is a systemic disease with an incidence of 1 to 40 per 100 000 persons per year. It predominantly affects people in the age of 20 to 40 years old. Disease course varies from mild self-limiting to chronic debilitating and life-threatening disease. Since the cause of sarcoidosis is unknown, curative therapy ...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.14.65

    authors: Crommelin HA,Vorselaars AD,van Moorsel CH,Korenromp IH,Deneer VH,Grutters JC

    更新日期:2014-01-01 00:00:00

  • Can IL-6 blockade rectify imbalance between Tregs and Th17 cells?

    abstract::Evaluation of: Pesce B, Soto L, Sabugo F et al. Effect of interleukin-6 receptor blockade on the balance between regulatory T cells and T helper type 17 cells in rheumatoid arthritis patients. Clin. Exp. Immunol. 171, 237-242 (2012). Clinical trials of a humanized anti-IL-6 receptor antibody, tocilizumab (TCZ), proved...

    journal_title:Immunotherapy

    pub_type: 评论,杂志文章

    doi:10.2217/imt.13.47

    authors: Tanaka T

    更新日期:2013-07-01 00:00:00

  • Cancer testis antigens as immunogenic and oncogenic targets in breast cancer.

    abstract::Breast cancer cells frequently express tumor-associated antigens that can elicit immune responses to eradicate cancer. Cancer-testis antigens (CTAs) are a group of tumor-associated antigens that might serve as ideal targets for cancer immunotherapy because of their cancer-restricted expression and robust immunogenicit...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt-2017-0179

    authors: Mahmoud AM

    更新日期:2018-07-01 00:00:00

  • Specific therapy to regulate inflammation in rheumatoid arthritis: molecular aspects.

    abstract::Rheumatoid arthritis (RA) is a chronic inflammatory disease in which persistent inflammation of synovial tissue results in a progressive functional decline of the joint and premature mortality. TNF inhibitors were the first biological disease-modifying antirheumatic drugs (DMARDs) used to treat RA. Since then, new bio...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.14.26

    authors: García-Hernández MH,González-Amaro R,Portales-Pérez DP

    更新日期:2014-01-01 00:00:00

  • Efficacy of a 3-year course of sublingual immunotherapy for mite-induced allergic rhinitis with a 3-year follow-up.

    abstract::Aim: To evaluate the long-term efficacy of sublingual immunotherapy (SLIT) in treating mite-sensitized allergic rhinitis (AR). Materials & methods: 150 AR children were randomly divided into SLIT and pharmacotherapy (PT) groups, receiving a 3-year course of SLIT along with PT or PT only. Results: The symptom and medic...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt-2020-0006

    authors: Chen WB,Shen XF,Li Q,Zhou WC,Cheng L

    更新日期:2020-08-01 00:00:00

  • Non-coding RNA and immune-checkpoint inhibitors: friends or foes?

    abstract::Non-coding RNAs (ncRNAs) are an abundant component of the human transcriptome. Their biological role, however, remains incompletely understood. Nevertheless, ncRNAs are highly associated with cancer development and progression due to their ability to modulate gene expression, protein translation and growth pathways. I...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt-2019-0204

    authors: Shek D,Read SA,Akhuba L,Qiao L,Gao B,Nagrial A,Carlino MS,Ahlenstiel G

    更新日期:2020-05-01 00:00:00

  • Novel immunotherapeutic strategies for pyelonephritis.

    abstract::Acute pyelonephritis is an infection of the renal parenchyma and renal pelvis. When it is caused by a typical pathogen in an immunocompetent female patient with normal urinary tract, it is considered uncomplicated. In all other cases, sepsis is the most worrisome complication. In the event of sepsis, patients should b...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.15.98

    authors: Tsaganos T,Giamarellos-Bourboulis EJ

    更新日期:2016-01-01 00:00:00

  • Vaccinia virus, a promising new therapeutic agent for pancreatic cancer.

    abstract::The poor prognosis of pancreatic cancer patients signifies a need for radically new therapeutic strategies. Tumor-targeted oncolytic viruses have emerged as attractive therapeutic candidates for cancer treatment due to their inherent ability to specifically target and lyse tumor cells as well as induce antitumor effec...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.15.90

    authors: Al Yaghchi C,Zhang Z,Alusi G,Lemoine NR,Wang Y

    更新日期:2015-01-01 00:00:00

  • Interview: Investigating immunomodulators among the Actinomycetales. Interview by Hannah Wilson.

    abstract::John L Stanford speaks to Hannah Wilson, Assistant Commissioning Editor John L Stanford is Chief Scientific Officer at BioEos Ltd (Kent, UK). Dr Stanford began his career as a senior lecturer and then reader in microbiology at Middlesex Hospital Medical School (London, UK), then University College London Medical Schoo...

    journal_title:Immunotherapy

    pub_type: 面试,新闻

    doi:10.2217/imt.13.27

    authors: Stanford JL

    更新日期:2013-05-01 00:00:00

  • The role of glial-neuronal metabolic cooperation in modulating progression of multiple sclerosis and neuropathic pain.

    abstract::While the etiology of multiple sclerosis (MS) remains unclear, research from the clinic and preclinical models identified the essential role of inflammation and demyelination in the pathogenesis of MS. Current treatments focused on anti-inflammatory processes are effective against acute episodes and relapsing-remittin...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt-2018-0153

    authors: Robinson RR,Dietz AK,Maroof AM,Asmis R,Forsthuber TG

    更新日期:2019-02-01 00:00:00

  • Updates and new perspectives in nonmelanoma skin cancer therapy: highlights from 'Immunotherapy Bridge'.

    abstract::Over the last few years, extensive research has improved our understanding of tumor immunology and has enabled the development of novel treatments. The state of the art of immunotherapy in various types of malignancies was exhaustively discussed in the 'Immunotherapy Bridge' meeting, which was held in Naples on 4-5 De...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt-2020-0042

    authors: Ascierto PA,Garbe C

    更新日期:2020-02-01 00:00:00

  • Phacilitate Barcelona active immunotherapeutics forum. 11-13 May 2011, Barcelona, Spain.

    abstract::The era of active immunotherapy has now been successfully ushered into the clinical realm of advanced prostate cancer. The successful clinical trial development and US FDA approval of sipuleucel-T (Provenge®) has revamped the therapeutic paradigm for advanced prostate cancer. Nonetheless, physician and patient educati...

    journal_title:Immunotherapy

    pub_type: 总体

    doi:10.2217/imt.11.90

    authors: Shore ND

    更新日期:2011-08-01 00:00:00

  • The role of the microbiome in childhood asthma.

    abstract::It is now well established that the healthy bronchial tree contains a microbiome distinct from that of the upper respiratory tract and that the lung microbiome may be dysregulated in individuals with a chronic respiratory disease, such as asthma. In addition, after birth, gut microbes interact with the host tissue, es...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt-2017-0048

    authors: Pisi G,Fainardi V,Aiello M,Bertorelli G,Crisafulli E,Chetta A

    更新日期:2017-11-01 00:00:00

  • Consequences of B-cell-depleting therapy: hypogammaglobulinemia and impaired B-cell reconstitution.

    abstract::Rituximab is a chimeric monoclonal antibody used to treat hematologic and autoimmune diseases by depleting CD20-expressing B cells. Patients may develop hypogammaglobulinemia following treatment, with some demonstrating failure of B-cell recovery. The true frequency of hypogammaglobulinemia and/or impaired B-cell reco...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt-2017-0178

    authors: Sacco KA,Abraham RS

    更新日期:2018-06-01 00:00:00

  • Reslizumab for pediatric eosinophilic esophagitis.

    abstract::Pediatric eosinophilic esophagitis is an inflammatory condition associated with marked eosinophil accumulation in the mucosal tissues of the esophagus. Eosinophils are major proinflammatory cells thought to make a major contribution to allergic diseases that affect the upper and lower airways, skin and GI tract. IL-5 ...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt.10.41

    authors: Walsh GM

    更新日期:2010-07-01 00:00:00

  • Engineering α-fetoprotein-based gene vaccines to prevent and treat hepatocellular carcinoma: review and future prospects.

    abstract::Activation of a patient's immune system offers an attractive approach to prevent and treat hepatocellular carcinoma (HCC). However, the antitumor efficacy of current HCC vaccines was weak owing to insufficient immune activation of targeting self/tumor antigens. We recently found that epitope-optimized α-fetoprotein ef...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.14.46

    authors: He Y,Hong Y,Mizejewski GJ

    更新日期:2014-01-01 00:00:00

  • New immunotherapeutic strategies for the treatment of neuroblastoma.

    abstract::The prognosis of high-risk neuroblastoma (NB) is still poor, in spite of aggressive multimodal treatment. Recently, adjuvant immunotherapy with anti-GD2 antibodies combined with IL-2 or GM-CSF has been shown to improve survival. Several other immunotherapy strategies proved efficacy in preclinical models of NB, includ...

    journal_title:Immunotherapy

    pub_type: 杂志文章,评审

    doi:10.2217/imt.14.117

    authors: Croce M,Corrias MV,Rigo V,Ferrini S

    更新日期:2015-01-01 00:00:00

  • Pseudoprogression of extramedullary disease in relapsed acute lymphoblastic leukemia after CAR T-cell therapy.

    abstract::Background: CD19-targeted chimeric antigen receptor (CAR) T-cell therapy has emerged as a powerful immunotherapy in relapsed or refractory B-cell acute lymphoblastic leukemia. The changes in extramedullary (EM) disease in pediatric relapsed or refractory B-cell acute lymphoblastic leukemia after CAR T-cell therapy hav...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt-2020-0188

    authors: Huang J,Rong L,Wang E,Fang Y

    更新日期:2021-01-01 00:00:00

  • JAK2 inhibition in murine systemic lupus erythematosus.

    abstract::Systemic lupus erythematosus is a systemic autoimmune disease characterized by the presence of myriad autoantibodies, some with pathogenic potential, and diverse clinical manifestations. Involvement of the kidney is a major cause of morbidity and mortality in human lupus patients and in murine models of the disease. I...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt.12.20

    authors: Tagoe C,Putterman C

    更新日期:2012-04-01 00:00:00

  • Optimizing tumor-targeting chimeric antigen receptor T cells in B-cell lymphoma patients.

    abstract::Evaluation of: Savoldo B, Ramos CA, Liu E et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J. Clin. Invest. 121(5), 1822-1826 (2011). Chimeric antigen receptor (CAR)-T cells are promising antitumor immunotherapies. However, there are limit...

    journal_title:Immunotherapy

    pub_type: 评论,杂志文章

    doi:10.2217/imt.11.135

    authors: Gandhi M,Jones K

    更新日期:2011-12-01 00:00:00

  • Chimeric antigen receptor T cells immunotherapy: challenges and opportunities in hematological malignancies.

    abstract::Taking advantage of the cellular immune system is the mainstay of the adoptive cell therapy, to induce recognition and destruction of cancer cells. The impressive demonstration of this principle is chimeric antigen receptor-modified T (CAR-T)-cell therapy, which had a major impact on treating relapsed and refractory h...

    journal_title:Immunotherapy

    pub_type: 杂志文章

    doi:10.2217/imt-2020-0181

    authors: El-Khazragy N,Ghozy S,Emad P,Mourad M,Razza D,Farouk YK,Mohamed NA,Ahmed MK,Youssef T,Bahnasawy YM,Elmasery S

    更新日期:2020-12-01 00:00:00

  • Carnitine deficiency and its possible risk factors in TB patients: first report.

    abstract:AIM:To assess carnitine serum levels and possible risk factors of its deficiency in patients with TB. PATIENTS & METHODS:All newly diagnosed TB patients admitted to an infectious diseases ward were recruited. Demographic, clinical and paraclinical characteristics of the patients were collected. Total carnitine serum c...

    journal_title:Immunotherapy

    pub_type: 临床试验,杂志文章

    doi:10.2217/imt.13.90

    authors: Hatamkhani S,Khalili H,Karimzadeh I,Abdollahi A,Jafari S,Khazaeipour Z

    更新日期:2013-09-01 00:00:00